<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732390</url>
  </required_header>
  <id_info>
    <org_study_id>peter 2 SECI</org_study_id>
    <nct_id>NCT04732390</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Erector Spinae Block for Acute Pain Management in Modified Radical Mastectomy</brief_title>
  <official_title>Analgesic Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Erector Spinae Block for Acute Pain Management in Modified Radical Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the analgesic efficacy of magnesium sulphate as adjuvants to levobupivacaine in&#xD;
      erector spinae plane block in modified radical mastectomy surgery for acute pain management&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participating female will be randomly allocated using computer generated randomization&#xD;
      program (http://www.randoiler.org) into one of 2 groups.&#xD;
&#xD;
      Group (C) / (I):20 patients (control group):&#xD;
&#xD;
      Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae&#xD;
      muscle at level of T5.&#xD;
&#xD;
      Group (M) / (III): 20 patients (magnesium slphate group):&#xD;
&#xD;
      Patient will receive 20ml 0.25% levobupivacaine above + 0.7 mg/kg MgSo4. The patient, the&#xD;
      anesthesiologist who administered the drugs and the data collector will be blinded to the&#xD;
      study drugs.&#xD;
&#xD;
      ** Study protocol&#xD;
&#xD;
      Pre-operative and post-operative procedure:&#xD;
&#xD;
      Premedication will be given, after complete fasting hours after applying standard monitors&#xD;
      (noninvasive blood pressure, pulse oximetery, ECG, temperature and capnography), an&#xD;
      intravenous cannula will be placed and secured.&#xD;
&#xD;
      Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting&#xD;
      position depending on surgical site (left or right) ESP block will be given using high&#xD;
      frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to&#xD;
      thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector&#xD;
      spinae muscle, are identified from surface, we deposite20 ml of 0.25% levobupivacaine into&#xD;
      interfacial plane below erector spinae muscle.&#xD;
&#xD;
      General anesthesia will be induced with fentanyl l μg /kg, propofol 2mg /kg, muscle relaxant&#xD;
      (atracurium 0.5 mg/kg) inhalational anesthesia (isoflurane or sevoflurane) No other narcotic,&#xD;
      analgesic or sedative will be administrated during operative period.&#xD;
&#xD;
      Standard monitor (mean arterial blood pressure, heart rate , oxygen saturation &amp; end-tidal&#xD;
      Co2) will observed and recorded every 30 min till end of surgery&#xD;
&#xD;
      Post-operative:&#xD;
&#xD;
      The patient will be transferred to the post anesthesia care unit (PACU) and will be monitored&#xD;
      for:&#xD;
&#xD;
        1. Vital signs (heart rate, noninvasive blood pressure, and oxygen saturation).&#xD;
&#xD;
        2. RASS score (Richmond Agitation &amp; Sedation scale) with its +4:-5 score range will be used&#xD;
           to assess sedation post-operative, considered sedation ≥-2 table (1)&#xD;
&#xD;
        3. Numerical Rating Score (NRS) pain score with its 0-10 score range will be used to assess&#xD;
           pain immediately post-operative and then at 2, 4, 6, 8, 12,18and 24hour in the&#xD;
           post-operative period figure (1).&#xD;
&#xD;
        4. Time and amount to request analgesia (PCA patient controlled analgesia morphine (demand&#xD;
           dose 1-2 mg, lock out 6-10 min)) at NRS≥3.&#xD;
&#xD;
        5. Side effect of studied drugs as (hypotension, sedation , respiration depression and&#xD;
           vomiting ) and complication of the block for 24h post- operative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesia request</measure>
    <time_frame>24 hours</time_frame>
    <description>first request for analgesia .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>GROUP(A) (CONTROL GROUP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (M)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block with bupivacaine</intervention_name>
    <description>Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5</description>
    <arm_group_label>GROUP(A) (CONTROL GROUP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block with bupivacaine and magnesium sulphate</intervention_name>
    <description>Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.</description>
    <arm_group_label>Group (M)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female patient&#xD;
&#xD;
          -  American society of anesthesiologists (ASA) I and II physical status&#xD;
&#xD;
          -  age from 25 to 70 years old&#xD;
&#xD;
          -  scheduled for either left or right modified radical mastectomy (MRM)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infection of the skin at or near site of needle puncture&#xD;
&#xD;
          -  coagulopathy,&#xD;
&#xD;
          -  drug hypersensitivity or allergy to the studied drugs,&#xD;
&#xD;
          -  central or peripheral neuropathy,&#xD;
&#xD;
          -  significant organ dysfunction cardiac dysrrhythmias,&#xD;
&#xD;
          -  obesity (BMI&gt;35kg/m2)&#xD;
&#xD;
          -  recently use analgesic drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>peter R Edward, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>specialist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>peter R Edward, MSc</last_name>
    <phone>1224083376</phone>
    <phone_ext>0020</phone_ext>
    <email>Peter_rafaat85@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>peter R Edward, MSc</last_name>
      <phone>1224083376</phone>
      <phone_ext>0020</phone_ext>
      <email>Peter_rafaat85@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter Rafaat Edward Iskander</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

